Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

Annals of Neurology

Volumn 39, Issue 2, 1996, Pages 147-157

  Gurney, Mark E ^a,c   Cutting, Frank B ^a   Zhai, Ping ^a   Doble, Adam ^b   Taylor, Charles P ^c   Andrus, Paula K ^c   Hall, Edward D ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SANOFI   (France)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; COPPER ZINC SUPEROXIDE DISMUTASE; GABAPENTIN; GLUTAMIC ACID; MEMBRANE LIPID; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIET SUPPLEMENTATION; DISEASE COURSE; LIPID PEROXIDATION; MOTOR NEURON DISEASE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SURVIVAL TIME; TRANSGENIC MOUSE;

ACETIC ACIDS; AMINES; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; CYCLOHEXANECARBOXYLIC ACIDS; DIET; DISEASE PROGRESSION; GAMMA-AMINOBUTYRIC ACID; HUMANS; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; RILUZOLE; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS; THIAZOLES; VITAMIN E;

EID: 0030050727     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390203     Document Type: Article

References (64)

1. Mulder DW. Clinical limits of amyotrophic lateral sclerosis. In: Rowland LP, ed. Human motor neuron diseases. New York: Raven Press, 1982:15-22
2. Emery AEH, Holloway S. Familial motor neuron diseases. In: Rowland LP, ed. Human motor neuron diseases. New York: Raven Press, 1982:139-147
3. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-6595
4. Spencer PS, Allen CN, Kisby GE, et al. Lathyrism and western Pacific amyotrophic lateral sclerosis: etiology of short and long latency motor system disorders. Adv Neurol 1991;56:287-299
5. Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci 1993;118:169-174
6. Yasui M, Yase Y, Ota K, Garruto RM. Aluminum deposition in the central nervous system of patients with amyotrophic lateral sclerosis from the Kii Peninsula of Japan. Neurotoxicology 1991;12:615-620
7. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634
8. Canu W, Billiard M, Baldy-Mouliner M. Fasting plasma and CSF amino acid levels in ALS. Acta Neurol Scand 1993;88:51-55
9. Plaitakis A, Constantakakis E. Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspatryl-glutamate in ALS. Brain Res Bull 1993;30:381-386
10. Rothstein J, Martin IJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in ALS. N Engl J Med 1992;326:1464-1468
11. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
12. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591
13. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu,Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62
14. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the develop-ment of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3:1757-1761
15. Brown RH Jr. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 1995;80:687-692
16. Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993;261:1047-1051
17. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993;61:2322-2325
18. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice expressing a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-1775
19. Ripps ME, Huntley GW, Hof PR, et al. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1995;92:689-693
20. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116
21. Dal Canto MC, Gurney ME. The development of CNS pathology in a murine transgenic model of human ALS. Am J Pathol 1994;145:1271-1280
22. Avraham KB, Sugarman H, Rotshenker S, Groner Y. Down's syndrome: morphological remodeling and increased complexity in the neuromuscular junction of transgenic CuZn-superoxide dismutase mice. J Neurocytol 1991;20:208-215
23. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12:1658-1667
24. Yang G, Chan PH, Chen J, et al. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke 1994;25:165-170
25. McCord JM. Mutant mice, Cu,Zn superoxide dismutase, and motor neuron degeneration. Science 1995;266:1586-1587
26. Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994;331:1721-1722 (Letter)
27. McCay PB. Vitamin E: interactions with free radicals and ascorbate. Annu Rev Nutr 1985;5:323-340
28. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994;44(suppl 5):S10-S16
29. Hallewell RA, Puma JP, Mullenbach GT, Najarian RC. Superoxide and superoxide dismutase. In: Rotilo G, ed. Chemistry, biology and medicine. New York: Elsevier, 1986:249-256
30. Epstein CJ, Avraham KB, Lovert M, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc Natl Acad Sci USA 1987;84:8044-8048
31. Lipman NS, Dalton SD, Stuart AR, Arruda K. Eradication of pinworms (Syphacta obvelata) from a large mouse breeding colony by combination oral antihelmintic therapy. Lab Anim Sci 1994;44:517-520
32. Chiu AY, Zhai P, Dal Canto MC, et al. Age-dependent penetrance of disease in a transgenic model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 1995;6:349-362
33. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis. Brain Res 1995;676:25-40
34. Zhang J-R, Andrus PK, Hall ED. Age-related changes in hydroxyl radical stress and antioxidants in gerbil brain. J Neurochem 1993;61:1640-1647
35. Reeves ED, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-1951
36. Vatassery GT, Brin MF, Fahn S, et al. Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver and adipose tissue of rats. J Neurochem 1988;51:621-623
37. Clarkson PM. Antioxidants and physical performance. Crit Rev Food Sci Nutr 1995;35:131-141
38. Yim MB, Chock PB, Stadtman ER. Copper,zinc superoxide dismutase catalyzes hydroxyl radical production from hydrogen peroxide. Proc Natl Acad Sci USA 1990;87:5006-5010
39. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:584 (Letter)
40. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. New York: Oxford University Press, 1989:1-543
41. Vatassery GT, Angerhofer CK, Knox CA. Effect of age on vitamin E concentrations in various regions of the brain and a few selected peripheral tissues of the rat, and on the uptake of radioactive vitamin E by various regions of rat brain. J Neurochem 1984;43:409-412
42. Hall ED, Yonkers PA, Horan KL, Braughler JM. Correlation between attenuation of post-traumatic spinal cord ischemia and preservation of spinal tissue vitamin E by the 21-aminosteroid lipid peroxidation inhibitor U-74006F: evidence for an in vivo antioxidant mechanism. J Neurotrauma 1989;6:169-176
43. Hall ED, Pazara KE, Braughler JM. Effects of tirilazad mesylate on post-ischemic brain lipid peroxidation and recovery of extracellular calcium in gerbils. Stroke 1991;22:361-366
44. Pelligrini-Giampietro DE, Cherici G, Alesiani M, et al. Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci 1990;10:1035-1041
45. Boisvert DPJ, Schreiber C. Interrelationship of excitotoxic and free radical mechanisms. In: Krieglstein J, Oberpichler H, eds. Pharmacology of cerebral ischemia. Stuttgart: Wissenshaftliche Verlaggesellschaft mbH, 1992:1-10
46. Tsuda T, Munthasser S, Fraser PE, et al. Analysis of the functional effects of a mutation in SOD1 associated with familial amyotrophic lateral sclerosis Neuron 1994;13:727-736
47. Pardo CA, Xu Z, Borchelt DR, et al. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA 1995;92:954-958
48. Braughler JM, Duncan LA, Chase RL. Interaction of lipid peroxidation and calcium in the pathogenesis of neuronal injury. CNS Trauma 1985;2:299-304
49. + pump ATPase of human red cell membranes. Biochem Pharmacol 1993;46:525-534
50. Malis CD, Bonventure JV. Susceptibility of mitochondrial membranes to calcium and reactive oxygen species: implications for ischemic and toxic tissue damage. In: Karnofsky ML, Leaf A, Bolis LC, eds. Biological membranes: aberration in membrane structure and function. New York: Alan R. Liss, 1988:235-259
51. Vlessis AA, Mela-Riker L. The potential role of mitochondrial calcium metabolism during reperfusion injury. Am J Physiol 1989;256:C1196-C1206
52. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108
53. Reiner A, Medina L, Figuerdo-Cardenas G, Anfinson S. Brainstem motoneuron pools that are selectively resistant in amyotrophic lateral sclerosis are preferentially enriched in parvalbumin: evidence from monkey brainstem for a calcium-mediated mechanism in sporadic ALS. Exp Neurol 1995;131:239-250
54. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993;250:473-476
55. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fiber. Pflugers Arch Eur J Pharmacol 1991;419:603-609
56. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-1060
57. Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994;177:95-99
58. Wahl F, Allix M, Plotkine M, Boulu RG. Effect of riluzole on focal cerebral ischemia in rats. Eur J Pharmacol 1993;230:209-214
59. Pratt J, Rataud J, Bardot F, et al. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett 1992;140:225-230
60. Boireau A, Dubedat P, Bordier F, et al. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 1994;5:2657-2660
61. Welty DF, Schielke GP, Rothstein JD. Potential treatment of amyotrophic lateral sclerosis by the anticonvulsant gabapentin: a hypothesis. Ann Pharmacother 1996 (In press)
62. Goldlust A, Su T-Z, Welty DF, et al. Effects of the anticonvulsant drug gabapentin on the enzymes in the metabolic pathways of glutamate and GABA. Epilepsy Res 1995;22:1-11
63. Loescher W, Hoenack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in regions of rat brain Neurosci Lett 1991;128:150-154
64. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995;65:643-651